SACS-AS1: A Potential Drug Target and Biomarker (G100506680)

Target Name: SACS-AS1

NCBI ID: G100506680

SACS-AS1

Other Name(s): SACS antisense RNA 1

SACS-AS1: A Potential Drug Target and Biomarker

Sodium channels are essential for the proper functioning of many physiological processes in the body. Sodium channels are involved in the regulation of neuronal excitability, muscle contractions, and inflammation. The SACS-AS1 gene is a sodium channel that has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders.

The SACS-AS1 gene is located on chromosome 11 and encodes a protein known as SACS-AS1. SACS-AS1 is a voltage-dependent sodium channel that is expressed in many different tissues and cells in the body. It is highly expressed in the brain and nervous system, and is also found in the heart, lungs, and kidneys.

SACS-AS1 functions as a voltage-dependent sodium channel, which means that it is sensitive to changes in the voltage of its intracellular environment. When the voltage of SACS-AS1 is increased, it opens and allows sodium ions to enter the cell. This process is known as depolarization or action potential, and is a critical step in the neural transmission process.

SACS-AS1 has been linked to a number of neurological and psychiatric disorders. For example, studies have shown that individuals with schizophrenia and bipolar disorder have lower levels of SACS-AS1 in their brain compared to healthy individuals. Additionally, SACS-AS1 has been shown to be involved in the development of epilepsy and other neurological conditions.

Furthermore, SACS-AS1 has also been identified as a potential biomarker for certain psychiatric disorders. For example, studies have shown that individuals with major depressive disorder have lower levels of SACS-AS1 in their brain compared to healthy individuals. Additionally, SACS-AS1 has been shown to be involved in the development of certain psychiatric disorders, such as depression and anxiety.

In addition to its potential clinical applications, SACS-AS1 also has potential as a drug target. By inhibiting the activity of SACS-AS1, researchers can potentially treat certain neurological and psychiatric disorders. For example, SACS-AS1 has been shown to be involved in the development of certain psychiatric disorders, so inhibiting its activity could potentially be a treatment for these disorders. Additionally, SACS-AS1 has also been shown to be involved in the regulation of neural activity, so targeting its activity could potentially lead to new insights into the underlying mechanisms of certain psychiatric disorders.

Overall, SACS-AS1 is a fascinating gene that has the potential to be a drug target and biomarker for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in these conditions, as well as its potential as a drug target.

Protein Name: SACS Antisense RNA 1

The "SACS-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SACS-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets